← Every company
Immunitybio Inc Patents
What Immunitybio Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
IBRX on carbonthat →Filings on file
50
Granted
3
Still pending
47
Filed under
2 names
50 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| Anktiva and Lymphocyte Rescue Compositions and MethodsA61P 35/00, C07K 14/5443, A61K 38/00, A61K 45/06, C07K 14/7155, C07K2319/30Filed as ImmunityBio, Inc.2026-03-05Patrick Soon-Shiong | pending |
| ANKTIVA AND LYMPHOCYTE RESCUE COMPOSITIONS AND METHODSFiled as IMMUNITYBIO, INC.2026-03-05PATRICK SOON-SHIONG | pending |
| Methods for Preparing and Storing Immortalized Cytolytic Natural Killer CellsC12N 5/526, C12N 5/0646, A61K 35/17, C12N 5/0693, C12N2510/04Filed as ImmunityBio, Inc.2026-03-03Shannyn Bessette | pending |
| METHODS OF REDUCING NEUROINFLAMMATIONA61K 38/17, A61K 38/1793, A61K 38/36, A61P 25/28, A61P 25/00, A61P 25/16, A61K 38/179, A61K 38/1841, A61K 38/20, A61K 38/2086Filed as ImmunityBio, Inc.2026-02-26Hing C. Wong | 12751994 |
| QUADRICISTRONIC SYSTEM COMPRISING A HOMING RECEPTOR AND CHIMERIC ANTIGEN RECEPTOR FOR STABLE GENETIC MODIFICATION OF CELLULAR IMMUNOTHERAPIESA61K 40/15, C07K 14/70535, C12N 5/0646, C12N 15/625, C12N 15/85, A61P 35/02, A61P 35/00, A61K2239/48, A61K2239/31, A61K2239/38, A61K 40/35, A61K 40/4219, A61K 40/30, A61K 40/4211, A61K 40/31, A61K 40/421, A01K2207/12, A01K2227/105, A01K2267/0331, A61K 9/0029, A61K 35/17, A61K 48/00, C07K 14/495, C07K 14/521, C07K 14/5434, C07K 14/5443, C07K 14/55, C07K 14/7051, C07K 14/70553, C07K 14/70564, C07K 14/70596, C07K 14/71, C07K 14/7158, C07K 14/82, C07K 16/2803, C07K 16/2827, C07K2317/622, C07K2319/02, C07K2319/03, C07K2319/33, C07K2319/74, C12N 15/90, C12N2510/00, C12N2750/14143Filed as ImmunityBio, Inc.2026-02-03Hans G. Klingemann | pending |
| INTRATUMORALLY INJECTED YEAST VACCINEA61P 35/04, A61K 39/00114, A61K 39/0011, A61P 35/00, A61K2039/86, A61K2039/82, A61K2039/80, A61K2039/876, A61K 39/39, A61K 39/3955, A61K2039/505, A61K2039/507, A61K2039/523, A61K2039/54, A61K2039/545, A61K2039/55516, A61K2039/585, C07K 14/5443, C07K 14/70575, C07K 14/7155, C07K 16/244, C07K 16/2818, C07K 16/2827, C07K 16/2875, C07K 16/2878, C07K2317/75, C07K2319/30Filed as ImmunityBio, Inc.2026-01-20Thomas H. King | pending |
| CHEMOKINE RESPONSIVE ACTIVATED NATURAL KILLER CELLS WITH SECONDARY HOMING ACTIVATION FOR VERIFIED TARGETSC07K 14/7158, C12N 5/0646, A61P 35/02, A61P 35/00, A61K2039/804, A61K2239/48, A61K2239/31, A61K2239/38, A61K 40/4219, A61K 40/4236, A61K 40/15, A61K 40/4211, A61K 40/31, A61K 35/17, A61K2039/5156, A61K2039/5158, C07K 14/521, C07K 14/523Filed as ImmunityBio, Inc.2026-01-07Nathan SCHOMER | pending |
| RECOMBINANT erIL-15 NK CELLSC07K 14/5443, C12N 15/63, A61P 35/00, A61K 40/35, A61K 40/30, A61K 40/15, A61K 40/4221, A61K 40/4211, A61K 40/31, A61K 40/421, A61K 35/17, A61K 38/00, C07K 14/7051, C07K 14/70535, C07K2319/02, C07K2319/04, C07K2319/33, C12N 5/0639, C12N 5/0646, C12N2501/2315, C12N2510/00, C12N2800/22Filed as ImmunityBio, Inc.2026-01-05Patrick Soon-Shiong | pending |
| MULTI-CHAIN CHIMERIC POLYPEPTIDES AND USE THEREOF IN THE TREATMENT OF LIVER DISEASESA61K 47/6813, A61K 38/1793, A61K 38/36, A61K 47/65, A61K 47/641, A61P 1/16, A61P 35/00, A61K 38/1841, A61K 38/2086Filed as ImmunityBio, Inc.2025-12-19Hing C. Wong | pending |
| INTERLEUKIN-15, PD-1 ANTIBODIES, AND TAXANES IN NON-SMALL CELL LUNG CANCERFiled as IMMUNITYBIO, INC.2025-12-03PATRICK SOON-SHIONG | pending |
| Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung CancerA61K 38/1793, C07K 14/7155, A61P 11/00, A61P 35/00, A61K2039/86, A61K 31/337, A61K 38/00, A61K 38/2086, A61K 39/395, A61K 39/39541, A61K 39/3955, A61K 39/39558, A61K2039/505, A61K2039/54, A61K2039/545, C07K 14/5443, C07K 16/244, C07K 16/2818, C07K 16/2827, C07K 16/2866, C07K2317/24, C07K2317/76, C07K2319/00, C07K2319/30, C07K2319/32, A61K2300/00Filed as ImmunityBio, Inc.2025-12-03Patrick Soon-Shiong | pending |
| NK-92 Cells with Cytokine Induced Memory-Like Cytotoxicity And Derivatives ThereofA61K 35/17, C07K 14/5434, A61P 35/00, A61K2239/47, A61K2239/59, A61K2239/53, A61K2239/48, A61K2239/31, A61K2239/49, A61K2239/38, A61K2239/54, A61K 40/35, A61K 40/4234, A61K 40/4205, A61K 40/42, A61K 40/4255, A61K 40/15, A61K 40/4211, A61K 40/31, A61K 40/421, A61K 40/11, C07K 14/70535, C12N 5/0018, C12N 5/0646, C12N2501/2312, C12N2501/2315, C12N2501/2318Filed as ImmunityBio, Inc.2025-11-24Hans G. Klingemann | pending |
| NK-92 CELLS WITH CYTOKINE INDUCED MEMORY-LIKE CYTOTOXICITY AND DERIVATIVES THEREOFFiled as IMMUNITYBIO, INC.2025-11-24HANS G. KLINGEMANN | pending |
| METHODS AND SYSTEMS FOR CELL BED FORMATION DURING BIOPROCESSINGC12M 25/20, C12M 23/14, C12M 27/10, C12M 29/14, C12M 29/18, C12M 33/10, C12M 41/36, C12M 47/02, C12N 5/0646Filed as ImmunityBio, Inc.2025-11-19Shannyn BESSETTE | pending |
| SINGLE-CHAIN CHIMERIC POLYPEPTIDES AND USES THEREOFC07K 16/18, C07K 16/2809, A61P 31/00, A61P 37/04, A61P 39/00, A61P 35/02, A61P 3/10, A61P 35/00, A61K 38/00, A61K 39/00, A61K2039/505, C07K 14/5443, C07K 14/55, C07K 14/745, C07K 16/2818, C07K 16/2866, C07K2317/24, C07K2317/31, C07K2317/56, C07K2317/622, C07K2317/70, C07K2317/74, C07K2317/92, C07K2319/00, C07K2319/02, C12N 5/0636, C12N 5/0637, C12N2501/998, C12N2510/00Filed as ImmunityBio, Inc.2025-11-14Hing Wong | pending |
| MODIFIED NK-92 haNK003 CELLS FOR THE CLINICA61K 35/17, A61K 48/005, C12N 5/0646, A61P 35/00, A61K2239/46, A61K2239/31, A61K2239/49, A61K2239/38, A61K 40/20, A61K 40/4205, A61K 40/15, A61K 38/177, A61K 38/1774, A61K 38/2013, A61K 39/395, A61K 48/00, A61K 48/0008, A61K2300/00, C07K 14/55, C07K 14/70535, C12N 15/85, C12N2510/00, C12N2840/203Filed as ImmunityBio, Inc.2025-11-10Hans Klingemann | pending |
| ELIMINATION OF PD-L1-POSITIVE MALIGNANCIES BY PD-L1 CHIMERIC ANTIGEN RECEPTOR-EXPRESSING NK CELLSA61P 35/04, A61K 40/15, C07K 14/70535, C12N 5/0646, A61P 35/00, A61K 39/001129, A61K 40/35, A61K 40/30, A61K 40/4224, A61K 40/31, A61K 40/421, A61K 35/17, A61K 38/00, A61K 39/395, A61K 39/39541, A61K2039/507, A61K2039/5154, A61K2039/5156, A61K2300/00, C07K 14/4702, C07K 14/54, C07K 14/5443, C07K 14/55, C07K 14/7051, C07K 16/2827, C07K2317/622, C07K2317/732, C07K2319/03, C12N 15/62, C12N2510/00Filed as ImmunityBio, Inc.2025-10-20Hans G. Klingemann | pending |
| DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLSB01D 21/01, G01N 33/56972, B01D 21/262, C07K 16/2896, C07K2317/622, C07K2319/00, C07K2319/33, C12N 9/6489, C12Y 304/24087Filed as ImmunityBio, Inc.2025-10-14Dr. Patrick SOON-SHIONG | pending |
| DUAL-SPECIFIC BINDING MOLECULE USEFUL FOR ISOLATING SPECIFIC BLOOD CELLSFiled as IMMUNITYBIO, INC.2025-10-14PATRICK SOON-SHIONG | pending |
| Enzyme Based System for Production of Messenger RNA with Increased Transfection EfficiencyC12N 15/70, C12P 19/34, C12N 9/1241, C12N 9/1247, C12Y 201/01056, C12Y 207/07006, C12Y 207/07019, C12Y 207/0705, C12Y 301/03003, C12Y 301/03033Filed as ImmunityBio, Inc.2025-09-25Brett Morimoto | pending |
| N-803 in the Treatment of MonocytopeniaFiled as ImmunityBio, Inc.2025-09-15Patrick Soon-Shiong | pending |
| COMBINED INVASTION AND CYTOTOXICITY ASSAY USING CHEMOKINE SECRETING TARGET CELLSG01N 33/5029, A61K 40/4234, A61K 40/4219, A61K 40/4202, A61K 40/15, A61K 40/4211, A61K 40/31, C07K 14/7051, C07K2319/03, C12M 41/46, G01N 33/5047, G01N2333/521Filed as ImmunityBio, Inc.2025-08-01Nathan Thomas SCHOMER | pending |
| COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTSFiled as IMMUNITYBIO, INC.2025-07-22FERDOUS ANOWER-E-KHUDA | pending |
| COMPOSITIONS AND METHODS RELATED TO POTENT CYTOTOXIC M-CENK CELLS FROM CD3/CD14-DEPLETED APHERESIS PRODUCTSA61K 35/17, C12N 5/0646, A61P 35/00, A61K 40/42, A61K 40/15, A61K 40/421, C07K 14/70503, C07K 16/2887, C07K2317/24, C07K2317/732, C12N 5/0018, C12N2501/2312, C12N2501/2315, C12N2501/2318, A61K2300/00Filed as ImmunityBio, Inc.2025-07-22Ferdous Anower-E-Khuda | pending |
| Neoepitope Vaccine Delivery Vehicle and Methods of Making the SameA61K 9/06, C12N 15/1055, A61K 47/61, A61K 47/6903, A61K 47/6939, A61K 38/063, A61K 39/385, A61K 41/0028, A61K 47/36, A61K2039/55583, C12N 15/87Filed as ImmunityBio, Inc.2025-07-16Philip T. Liu | pending |
| Anktiva, G-CSF, and Lymphocyte Rescue Compositions and MethodsFiled as ImmunityBio, Inc.2025-06-30Patrick Soon-Shiong | pending |
| ANTI-SLAMF7 ANTIBODIES AND THERAPEUTICSFiled as IMMUNITYBIO, INC.2025-06-25CLIFFORD ANDERS OLSON | pending |
| Anti-SLAMF7 Antibodies And TherapeuticsC07K 16/2803, A61P 35/00, A61K 40/4224, A61K 40/15, A61K 40/31, A61K 40/11, A61K 38/2086, A61K 39/39558, A61K2039/505, C07K 14/5443, C07K 14/7155, C07K2317/31, C07K2317/33, C07K2317/35, C07K2317/526, C07K2317/55, C07K2317/567, C07K2317/73, C07K2317/732, C07K2317/76, C07K2317/92, C07K2319/00Filed as ImmunityBio, Inc.2025-06-25Clifford Anders OLSON | pending |
| Primary NK CAR Constructs And MethodsC07K 14/55, C07K 14/7051, C12N 5/0646, A61P 35/02, A61P 35/04, A61P 35/00, A61K 39/001111, A61K 39/00114, A61K 40/4234, A61K 40/15, A61K 40/31, A61K 40/421, A61K 45/06, A61K2039/5156, C07K 14/705, C07K 14/70521, C07K 14/70535, C07K 14/70596, C07K 16/2827, C07K2317/622, C07K2317/732, C07K2319/00, C07K2319/02, C07K2319/03, C07K2319/33, C07K2319/74, C12N 5/06, C12N 5/0638, C12N 5/10, C12N 15/62, C12N 15/65, C12N 15/85, C12N2510/00, C12N2800/107, C12N2830/001, C12N2830/50, C12N2840/203Filed as ImmunityBio, Inc.2025-06-24Fereshteh Parviz | pending |
| FIDUCIAL LOCALIZATION WITH SPARSE ANNOTATIONSG06T 11/26, A61B 5/352, A61B 5/7267, G06T2210/22, G06T2210/41Filed as ImmunityBio, Inc.2025-06-06Matheen Siddiqui | pending |
| Anktiva and Lymphocyte Rescue Compositions and MethodsFiled as ImmunityBio, Inc.2025-05-28Patrick Soon-Shiong | pending |
| METHODS OF TREATING BRONCHOPULMONARY DYSPLASIAA61K 38/1841, A61P 11/00, A61K 38/2086, A61K 38/36Filed as ImmunityBio, Inc.2025-05-20Hing C. Wong | pending |
| CONTENT AUTHENTICATION AND VALIDATION VIA MULTI-FACTOR DIGITAL TOKENS, SYSTEMS, AND METHODSG06F 21/32, G16B 50/40, G06F 21/602, G06F 21/645, G06F 21/33Filed as ImmunityBio, Inc.2025-05-19Luna Witchey | pending |
| ELIMINATION OF CD19-POSITIVE LYMPHOID MALIGNANCIES BY CD19-CAR EXPRESSING NK CELLSA61P 35/00, C07K 14/70535, C12N 5/0646, A61P 35/02, A61P 35/04, A61K2039/804, A61K2239/13, A61K2239/48, A61K2239/31, A61K 40/15, A61K 40/4211, A61K 40/31, A61K 9/0019, A61K 38/00, A61K2039/54, C07K 14/5443, C07K 14/55, C07K 14/70503, C07K 14/7051, C07K 16/2803, C07K 16/2887, C07K2317/622, C07K2317/732, C07K2317/76, C07K2319/02, C07K2319/03, C07K2319/30, C07K2319/33, C12N 15/85, C12N2510/00, C12N2800/107, C12N2830/20, C12N2840/20, C12N2840/203Filed as ImmunityBio, Inc.2025-05-13Hans G. Klingemann | pending |
| Anktiva and Lymphocyte Rescue Compositions and MethodsFiled as ImmunityBio, Inc.2025-05-05Patrick Soon-Shiong | pending |
| Interleukin-15, PD-1 Antibodies, and Taxanes in Non-Small Cell Lung CancerFiled as ImmunityBio, Inc.2025-04-25Patrick Soon-Shiong | pending |
| COMPOSITIONS AND METHODS FOR PRODUCING IL-16Filed as IMMUNITYBIO, INC.2025-04-17BARRY SIMON | pending |
| INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVIDA61K 38/2086, A61P 31/14, A61K 9/0019, A61K 38/1793, A61K 39/215, A61K2039/545, C07K 14/5443, C07K 14/7155, C07K 16/283, C07K2319/00, C07K2319/30, C07K2319/33Filed as ImmunityBio, Inc.2025-04-08Patrick Soon-Shiong | pending |
| INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVIDFiled as IMMUNITYBIO, INC.2025-04-08PATRICK SOON-SHIONG | pending |
| Compositions and Methods for NK-92 Cells Expressing Native CD16C12N 5/0646, G01N 33/6845, C07K 14/70535, C12N 15/907, C12N2503/00, C12N2510/00, G01N 33/56972, G01N2333/70535Filed as ImmunityBio, Inc.2025-03-20Barry J. Simon | 12681020 |
| Anti COVID-19 Therapies targeting nucleocapsid and spike proteinsA61K 39/215, A61P 31/14, A61K 39/39, A61K2039/545, A61K2039/55505, C07K2319/06, C12N 15/86, C12N 15/861, C12N2710/10343, C12N2770/20022, C12N2770/20034Filed as ImmunityBio, Inc.2025-03-14Patrick Soon-Shiong | pending |
| Anktiva and Lymphocyte Rescue Compositions and MethodsFiled as ImmunityBio, Inc.2025-03-10Patrick Soon-Shiong | pending |
| Anktiva and Lymphocyte Rescue Compositions and MethodsFiled as ImmunityBio, Inc.2025-03-07Patrick Soon-Shiong | pending |
| DISTRIBUTED LEDGER FOR MEDICAMENT ADMINISTRATION TRACKINGG16H 20/13, G07C 9/00896, G16H 20/17, G07C 9/00182Filed as ImmunityBio, Inc.2025-03-07Patrick Soon-Shiong | 12712061 |
| Adenoviral Vector Transduced Apheresis ProductA61K 40/24, A61K 40/4201, C12N 15/86, A61P 37/00, A61P 31/00, A61P 35/00, A61K2239/31, A61K2239/38, A61K2239/39, A61K 40/4205, A61K 40/42, A61K 40/15, A61K 40/31, C07K 14/4748, C07K 14/5443, C12N 5/0636, C12N 5/0646, C12N2501/22, C12N2501/2302, C12N2501/2307, C12N2501/2315, C12N2501/26, C12N2710/10343, C12N2710/10362Filed as ImmunityBio, Inc.2025-03-05Patrick Soon-Shiong | pending |
| SYSTEM AND METHOD FOR ADMINISTERING A PHARMACEUTICAL COMPOSITION WITH AN INTRAVENOUS TUBING SETA61M 5/1408, A61M 39/28, A61M 5/14, A61M 5/1407, A61M 5/162, A61M 5/168, A61M 39/08, A61M 39/10, A61M 39/20Filed as ImmunityBio, Inc.2025-02-26Kathleen Adlard | pending |
| SYSTEM AND METHOD FOR ADMINISTERING A PHARMACEUTICAL COMPOSITION WITH AN INTRAVENOUS TUBING SETFiled as IMMUNITYBIO, INC.2025-02-26KATHLEEN ADLARD | pending |
| CHIMERIC ANTIGEN RECEPTOR-MODIFIED NK-92 CELLS TARGETING EGFR SUPER-FAMILY RECEPTORSC12N 5/0646, A61P 35/00, A61K2239/50, A61K2239/31, A61K2239/38, A61K 40/4205, A61K 40/4204, A61K 40/15, A61K 40/31, A61K 45/06, C07K 14/5434, C07K 14/5443, C07K 14/55, C07K 14/70535, C07K 14/71, C07K 16/2863, C07K 16/32, C07K2317/24, C07K2317/53, C07K2317/622, C07K2317/732, C07K2319/02, C07K2319/03, C07K2319/30, C07K2319/33Filed as ImmunityBio, Inc.2025-01-22John H. Lee | pending |
| TREATMENT OF MHC-I NEGATIVE TUMORS WITH NK AND T CELLSA61K 40/15, A61K 40/31, A61K 40/11, A61P 35/00, A61K 40/35, A61K 40/4235, A61K 40/32, A61K 31/20, A61K 31/502, A61K 31/573, A61K 31/7068, A61K 31/7072, A61K 31/7105, A61K 35/17, A61K 38/2086, A61K 38/217, A61K 45/06, A61K2300/00, C07K 16/00, G01N 33/6893Filed as ImmunityBio, Inc.2025-01-21Patrick Soon-Shiong | pending |
| TUMORICIDAL AND ANTIMICROBIAL COMPOSITIONS AND METHODSA61K 35/17, C12N 5/0646, Y02A 40/70, A61P 37/02, A61P 31/00, A61P 35/00, A61K2239/38, A61K 40/44, A61K 40/15, A61K 9/0014, A61K 9/0019, A61K 9/06, A61K 9/08, A61K 9/5068, A61K 38/2013, A61K2035/124, C12N2500/32, C12N2500/90, C12N2501/2302, C12N2501/2315, C12N2501/24, C12N2509/00, A61K2300/00Filed as ImmunityBio, Inc.2025-01-17Hans G. Klingemann | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on IBRX
Company overviewEverything on IBRX in one place, with the price.SEC filingsWhat IBRX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat IBRX's own officers and directors buy and sell.Planned salesSales IBRX insiders have filed notice of.Executive payWhat IBRX awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in IBRX.Funds holding itWhich funds and ETFs hold IBRX, and how big a bet.LobbyingWhat IBRX spends lobbying Congress, and on what.